Lumos Pharma, Inc.

NasdaqGM:LUMO Stock Report

Market Cap: US$37.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Lumos Pharma Management

Management criteria checks 3/4

Lumos Pharma's CEO is Rick Hawkins, appointed in Jan 2011, has a tenure of 13.92 years. total yearly compensation is $952.87K, comprised of 61.1% salary and 38.9% bonuses, including company stock and options. directly owns 8.64% of the company’s shares, worth $3.24M. The average tenure of the management team and the board of directors is 4.7 years and 8.8 years respectively.

Key information

Rick Hawkins

Chief executive officer

US$952.9k

Total compensation

CEO salary percentage61.1%
CEO tenure13.9yrs
CEO ownership8.6%
Management average tenure4.7yrs
Board average tenure8.8yrs

Recent management updates

Recent updates

We're A Little Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate

May 23
We're A Little Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate

We're Keeping An Eye On Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate

Aug 25
We're Keeping An Eye On Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate

Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Deliver On Growth Plans?

Mar 13
Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Deliver On Growth Plans?

Lumos Pharma announces new buyback program

Aug 16

Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation

Mar 22
Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation

Companies Like Lumos Pharma (NASDAQ:LUMO) Are In A Position To Invest In Growth

Nov 04
Companies Like Lumos Pharma (NASDAQ:LUMO) Are In A Position To Invest In Growth

What Kind Of Investors Own Most Of Lumos Pharma, Inc. (NASDAQ:LUMO)?

Dec 09
What Kind Of Investors Own Most Of Lumos Pharma, Inc. (NASDAQ:LUMO)?

Lumos Pharma (LUMO) Investor Presentation - Slideshow

Nov 17

Lumos Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 11

CEO Compensation Analysis

How has Rick Hawkins's remuneration changed compared to Lumos Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$35m

Jun 30 2024n/an/a

-US$36m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$953kUS$583k

-US$34m

Sep 30 2023n/an/a

-US$33m

Jun 30 2023n/an/a

-US$32m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$1mUS$582k

-US$31m

Sep 30 2022n/an/a

-US$28m

Jun 30 2022n/an/a

-US$29m

Mar 31 2022n/an/a

-US$30m

Dec 31 2021US$1mUS$571k

-US$30m

Sep 30 2021n/an/a

-US$27m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021n/an/a

-US$15m

Dec 31 2020US$2mUS$516k

-US$6m

Compensation vs Market: Rick's total compensation ($USD952.87K) is above average for companies of similar size in the US market ($USD642.40K).

Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.

CEO

Rick Hawkins (75 yo)

13.9yrs

Tenure

US$952,869

Compensation

Mr. Richard J. Hawkins, also known as Rick, is Operating Partner of Havencrest Healthcare Partners. He is the Founder of Lumos Pharma, Inc. and has been its Chairman of the Board since March 26, 2020, its...

Leadership Team

NamePositionTenureCompensationOwnership
Richard Hawkins
Founder13.9yrsUS$952.87k8.64%
$ 3.2m
John McKew
Chief Scientific Officer & President8.7yrsUS$904.79k0.036%
$ 13.6k
Lori Lawley
CFO & Principal Accounting Officer4.8yrsUS$569.78k0.10%
$ 38.5k
Lisa Miller
Senior Director of Investor Relationsno datano datano data
Bradley Powers
Chief Compliance Officer & General Counsel9.3yrsUS$853.06k0.047%
$ 17.8k
Aaron Schuchart
Chief Business Officer4.6yrsno data0.049%
$ 18.5k
Pisit Pitukcheewanont
Chief Medical Officer1.5yrsno data0.056%
$ 21.0k
Alpa Parikh
Senior Vice President of CMC & Supply Managementless than a yearno datano data
Eddie Varnado
Corporate Controller3.7yrsno datano data

4.7yrs

Average Tenure

58yo

Average Age

Experienced Management: LUMO's management team is considered experienced (4.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Richard Hawkins
Founder13.9yrsUS$952.87k8.64%
$ 3.2m
Lota Zoth
Independent Director12.1yrsUS$69.33k0.025%
$ 9.5k
Joseph S. McCracken
Independent Director4.8yrsUS$56.33k0.18%
$ 68.2k
Kevin Lalande
Independent Director10.8yrsUS$54.33k0.012%
$ 4.7k
Thomas Raffin
Lead Independent Director25.9yrsUS$86.83k0.11%
$ 40.8k
George Werther
Member of Scientific Advisory Boardno datano datano data
Chad Johnson
Independent Director6.8yrsUS$64.33k0.012%
$ 4.7k
An van Es-Johansson
Independent Director3.8yrsUS$52.83k0.0099%
$ 3.7k
Ron Rosenfeld
Member of Scientific Advisory Boardno datano datano data
Peter Clayton
Member of Scientific Advisory Boardno datano datano data
Reiko Horikawa
Member of Scientific Advisory Boardno datano datano data
Mark Bach
Scientific Advisory Board Member3.4yrsno datano data

8.8yrs

Average Tenure

65.5yo

Average Age

Experienced Board: LUMO's board of directors are considered experienced (8.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/13 11:50
End of Day Share Price 2024/12/11 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lumos Pharma, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertD. Boral Capital LLC.
Eun Kyung YangJefferies LLC
Elemer PirosRoth MKM